CMV
Minnesota Congenital CMV Screening Program Shows Promise
A universal newborn screening and population-based surveillance program for congenital cytomegalovirus, which was ...
AUGUST 29, 2024
Assay Predicts Protection From CMV Events
There is a growing interest in assays that measure CMV-specific T-cell immunity, which may predict inherent ...
FEBRUARY 7, 2024
New Indication for Prevymis to Prevent CMV in High-Risk Kidney Transplant Recipients
The FDA granted a new indication for letermovir for prophylaxis of CMV disease in high-risk adult kidney transplant ...
JUNE 6, 2023
Decisions Expected Soon for 2 sNDAs for Prevymis
The FDA is expecting to decide on Merck’s request for two sNDAs for its CMV Prevymis: one on June 5 and the ...
APRIL 5, 2023
Cytomegalovirus Vaccine in Final Stages of Development
A vaccine for cytomegalovirus (CMV), a common, yet not particularly well-known, virus linked to high rates of birth ...
JULY 11, 2022
What’s New in CMV Prevention and Therapy for Transplant Patients?
Infection and disease caused by the human cytomegalovirus (CMV) remains a challenge in transplant recipients.
APRIL 11, 2022
Managing Post-Transplant Refractory/Resistant CMV
Cytomegalovirus infection is the most common infectious complication in solid organ and hematopoietic stem cell ...
JANUARY 5, 2022
FDA Grants New Indication for Orencia for Acute Graft-Versus-Host Disease Prophylaxis
Acute GvHD affects up to 70% of patients who receive an HSCT, particularly those coming from unrelated and ...
DECEMBER 17, 2021
FDA Approves Livtencity for Resistant Post-Transplant CMV
Although a rare disease overall, CMV is one of the most common infections experienced by both HSCT and SOT ...
NOVEMBER 24, 2021
FDA Advisory Committee Recommends Maribavir for Post-Transplant Recipients With Refractory CMV
ADAC recently recommended approval for the investigational cytomegalovirus treatment, maribavir (Takeda ...
OCTOBER 12, 2021
FDA Clears First Test for Detecting CMV in Newborns
CMV is the most common congenital infection and a leading cause of childhood cognitive deficits, hearing loss and ...
DECEMBER 11, 2018
Letermovir Prophylaxis Lowers CMV Risk in HCT Patients
The recently approved antiviral drug letermovir (Prevymis, Merck) significantly lowered the risk for clinically ...
APRIL 6, 2018
